Navigation Links
Labopharm settles $1 million draw down under standby equity distribution agreement
Date:1/8/2010

the U.S., Canada, the United Kingdom, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. and Canada and the Company has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. Labopharm also has a pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Except as required by law, the Company undertakes no obligation and does not intend to update these forward-looking statements.

SOURCE Labopharm Inc.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
2. Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
3. Labopharm Reports Results for Third Quarter Fiscal 2009
4. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
5. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
6. Labopharm submits response to FDA for novel antidepressant
7. Labopharm Reports Results for Second Quarter Fiscal 2009
8. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
9. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
10. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
11. Labopharm amends debt facility agreement with Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... New Jersey (PRWEB) May 04, 2015 Parlin ... to give a chance to more youths to participate and ... encourage youths in her area to do good deeds and ... Dr.Blagoev intends to empower their minds and teach them to ... contest is accessible to any youth 18 years of age ...
(Date:5/4/2015)... May 05, 2015 The ... Irene Taylor , Volunteer Executive Director of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor," said NAPW President Star Jones. "Her ...
(Date:5/4/2015)... May 05, 2015 The National ... Weis as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in healthcare. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
(Date:5/4/2015)... , May 4, 2015  The board of directors ... declared a dividend for the second quarter of 2015 of ... The dividend is payable June 10, 2015, to shareholders of ... About Eli Lilly and Company Lilly is a global ... better for people around the world. We were founded more ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
(Date:5/4/2015)... May 4, 2015 PharmaEngine, Inc. (TWO:4162) ... Inc. (NASDAQ: MACK ) with its sublicensing ... jointly announced that Baxter has submitted a marketing ... (EMA) for MM-398 (irinotecan liposome injection), also known ... the pancreas who have been previously treated with ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
Solid 14 mm blades. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Speculum with malleable plate to support flap during ablation of thestromal bed....
Medicine Products: